Acrivon Therapeutics, Inc.
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$77.9M
- Total assets
- $129.7M
- Market cap
- $61.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $84.1M
- Operating income
- -$84.1M
- Income tax
- $0
- Net income
- -$77.9M
- EPS (basic)
- $-2.02
- EPS (diluted)
- $-2.02
Balance sheet
- Total assets
- $129.7M
- Current assets
- $120.4M
- Total liabilities
- $17.2M
- Current liabilities
- $15.7M
- Shareholders’ equity
- $112.5M
Cash flow
- Operating cash flow
- -$63.7M
- Investing cash flow
- $66.1M
- Financing cash flow
- -$749.0K
- Net cash flow
- $1.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $61.2M
- EPS (diluted)
- $-2.02
- Shares outstanding
- 43.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 15, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $77.9M.
- Trading 53% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Acrivon Therapeutics, Inc..
Write a review
News about Acrivon Therapeutics, Inc.
News & sentiment via Polygon.io
